FDG PET/CT在肺结节病中的应用:现状与未来展望
本综述总结了FDG-PET/CT在肺结节病中检测活动性肺部炎症、指导活检、评估多系统受累及监测治疗反应等方面的现有证据,指出其缺乏标准化判读标准等局限性,并展望影像表型分析、放射组学与人工智能等未来方向。
要点
- FDG-PET/CT可功能评估代谢活性,在心脏结节病中已有明确用途,肺部应用证据持续增加。
- 可用于检测活动性肺部炎症、指导活检、评估多系统受累及监测治疗反应。
- 主要局限为缺乏标准化判读标准及临床决策差异,常规应用仍需前瞻性验证。
核心结论
- FDG-PET/CT有望用于基于活动度的肺结节病个体化评估,但需进一步验证以支持常规临床采用。
研究设计与样本
- 本文为综述,评估FDG-PET/CT在肺结节病中应用的当前证据并探讨未来方向。
主要发现
- FDG-PET/CT在心脏受累中已有明确用途,在肺部疾病中的作用证据正在增加。
- 该检查可用于检测活动性肺部炎症、指导活检、评估多系统受累和监测治疗反应。
- 缺乏标准化判读标准和临床决策差异是其主要局限性。
临床怎么用
- 在肺结节病评估中可考虑FDG-PET/CT作为辅助手段,用于活动性炎症检测、活检引导、多系统评估及治疗反应监测。
局限性
- 缺乏标准化判读标准,临床决策存在差异,常规应用仍需前瞻性研究和循证指南支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary sarcoidosis is a heterogeneous granulomatous disease with an unpredictable clinical course, in which accurate assessment of disease activity remains a major clinical challenge. Although up to two-thirds of newly diagnosed patients experience spontaneous remission, a significant proportion develop chronic or relapsing disease. Distinguishing self-limiting inflammation from progressive disease remains inherently difficult and has important therapeutic implications. 2-deoxy-2-[18F] fluoro-d-glucose (FDG) positron emission tomography/computed tomography (FDG-PET/CT) provides functional assessment of metabolic activity and has emerged as a valuable adjunct in sarcoidosis, with established utility in cardiac involvement and growing evidence supporting its role in pulmonary disease. This review examines the current evidence for the use of FDG-PET/CT in detecting active pulmonary inflammation, guiding biopsy, assessing multisystem involvement, and monitoring treatment response, and discusses its evolving integration into clinical care. We also highlight key limitations, including lack of standardized interpretation criteria, and variability in clinical decision-making. Finally, future directions are explored, with emphasis on imaging-based phenotyping, radiomics and artificial intelligence, quantitative and volumetric PET metrics, integration with clinical and serum biomarkers, and the need for prospective studies and evidence-based guidelines. Collectively, these developments position FDG-PET/CT as a promising tool for activity-based, personalized assessment of pulmonary sarcoidosis, while underscoring the need for further validation to support routine clinical adoption.
引用
- Donnelly R, Boyle N, McCarthy C, et al. FDG PET in pulmonary sarcoidosis: An update and future aspects. Semin Nucl Med. 2026. PMID: 41936480. doi:10.1053/j.semnuclmed.2026.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。